Lupin launches generic solution for conjuctivitis in US

Mumbai, Oct 3 : Drug maker Lupin Thursday said it has launched the generic version of Allergan Inc's Zymaxid Ophthalmic Solution in the US market with 180 days of marketing exclusivity.

Lupin Pharmaceuticals Inc, the company's US subsidiary, launched its generic Gatifloxacin Ophthalmic Solution 0.5 percent in the US market, after having received the regulator's final approval earlier, Lupin said in a statement.

Gatifloxacin Ophthalmic Solution 0.5 percent, which is the generic equivalent of Zymaxid Ophthalmic Solution of Allergan, is indicated for the treatment of bacterial conjunctivitis.

"Zymaxid Ophthalmic Solution 0.5 percent had annual US sales of around USD 62.3 million, acording to IMS MAT data. Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Zymaxid Ophthalmic Solution and as such will be entitled to 180 days of marketing exclusivity," the company said.

Lupin has been focusing on less competitive specialities spaces in the US market which includes segments like Oral Contraceptives, Ophthalmology and Dermatology.

--IANS (Posted on 03-10-2013)

pharmaceutical-news headlines

Sanofi appoints N Rajaram as Country Head & GM (Pharma operations)

Nutraceuticals slams FSSAI 'Product Approval' scheme

Some facts about drug over which Powell banned

Lupin gets USFDA nod for diabetes management drug

Sun Pharma to acquire Ranbaxy for USD four billion in all stock transaction

Sun Pharma to buy Ranbaxy for $4 billion in all-share deal

Venus gets marketing nod from Venezuela for meropenem

Venus gets marketing nod from Venezuela for infection drug

Jubilant Life to develop new drugs to combat TB

Jubilant gets $3.4 mn for new anti-TB drugs

Prolonged crisis in Ukraine could affect Indian pharma companies

Strand receives US patent for virtual liver

Quick Links: Goa | Munnar | Pondicherry | Free Yearly Horoscope '2014


Your e-mail:

Your Full Name:

Type verification image:
verification image, type it in the box


Back to Top